UBS Initiates Coverage on Integra LifeSciences Holdings Corporation (IART) with Neutral

Market Context

Integra LifeSciences Holdings Corporation operates in the Healthcare sector. The stock currently trades at $19.76 with a market capitalization of $1.1B. The stock has gained 53.7% over the past 52 weeks.

Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Integra LifeSciences Holdings Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Integra LifeSciences Holdings Corporation

Among the 10 most recent ratings: 0 Buy, 8 Hold, 2 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	UBS	Neutral	N/A
Jul 16, 2026	Truist Securities	Hold	N/A
Jul 09, 2026	BMO Capital	Market Perform	N/A
Jul 08, 2026	Citigroup	Neutral	N/A
May 28, 2026	Citigroup	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View IART Stock Page